Key talking points: Brazil, $5.6 million guidance, actual revenues less than 5% of guidance.
That turned out to be the template for every "positive" press release for this company since 1996. Pick a country -- any country -- and predict $$$ millions in revenues. Results: less than 5% of guidance.
Three CEO's later (Dreher, MacLellan, Charter).... at least this new CEO isn't giving false guidance. That's a positive, I guess.
As for Radient and Provista in 2010... Provista got smart and backed out. Then the CEO at the time, Gartner, left Provista. Then Provista dropped their lung cancer test from their pipeline. The clinicals and trials for every other Provista test specifically omits DR-70 and/or onko-sure. Provista can't secretly be adding DR-70 to their test and not telling anyone. Science is science.
End of story. Provista has out of the Radient picture for a long time. Only Wishful Thinking can establish a tie between Radient and Provista now.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.